Whatever the initial efficacy of the treatment undertaken in the metastatic setting, almost every patient will relapse. Progression-free survival (PFS) is one of surrogate markers of overall survival. To achieve this, the type of chemotherapy, the optimal duration of chemotherapy, the benefit of maintenance chemotherapy, and the benefit of maintenance hormonal treatment need to be clarified.
Aromatase inhibitors (AIs) are highly active in postmenopausal women with positive-hormone receptor breast cancer. However, AIs do not suppress ovarian estrogen synthesis and are not effective in premenopausal women. Luteinising hormone-releasing hormone (LH-RH) analogs, which produce a persistent reduction in estradiol levels in the range of postmenopausal values, probably represent a more appropriate pharmacological approach to advanced breast cancer in premenopausal women. Nonetheless, the combination of an LH-RH analog and tamoxifen is now accepted as patients were provided a thorough explanation of the study, and they signed informed consent prior to enrollment into the study.
Hormone receptor and HER2/neu status
All immunohistochemical studies of HER-2/neu, ER and PgR, were performed on 4-mm sections of formalin-fixed, paraffin-embedded tissues in the department of pathology. All three antibodies were from Roche Chemicon. The staining was performed using the standard streptavidin-biotin system on an automated immunostainer (Novocastra, Leica Biosystems Newcastle Ltd. UK). The percentage of positive cells was semiquantified manually. ER and PgR positivity was defined as nuclear staining in more than 10% of tumor cells, as St Gallen 2005 stated for "endocrine responsive" [8] . Based on American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) guidelines [9] , for HER2, a positive result is IHC staining of 3+ (uniform, intense membrane staining of 30% of invasive tumor cells). An equivocal result (2+) is complete membrane staining that is either nonuniform or weak in intensity but with obvious circumferential distribution in at least 10% of cells. A negative HER2 test is defined as either an IHC result of 0 or 1+ for cellular membrane protein expression (no staining or weak, incomplete membrane staining in any proportion of tumor cells). In two patients with a score of 2+; one was reanalyzed as positive using FISH, and the other was classified as negative by default without further examination. Results of hormone receptor status and HER2/neu assessment are given in Table 1 .
Treatment
All patients received goserelin (Zoladex, AstraZeneca) 3.6 mg by subcutaneous injection every 4 weeks along with letrozole 2.5 mg daily (Femara, Novartis Pharma). Patients with stable disease or responding disease were continued on the study drugs until disease progression was documented or until serious toxicity or other conditions necessitating discontinuation of therapy occurred. PFS was taken as the end point of this study.
Assessment of response
Baseline evaluations were performed within 1 month prior to the first study treatment dose and included physical examination, bone scan, chest x-rays or pulmonary CT scan, liver ultrasound (US) or liver CT scan, the treatment of choice in premenopausal MBC patients. A promising new option could be the combination of an LH-RH analog and an AI. The Austrian Breast and Colorectal Cancer Study Group (ABCSG-12) reported results showing that goserelin plus anastrozole yielded clinical outcomes that were similar to those of goserelin plus tamoxifen in premenopausal women with hormone-responsive early breast cancer [4] . However, very little data about goserelin with anastrozole in advanced breast cancer are currently available [5] [6] [7] . To the best of our knowledge, no cohort studies on the efficacy of goserelin plus letrozole in advanced breast cancer patients who had progressed on more than one cytotoxic or hormonal treatment have been reported.
We now report the results of a single-center, retrospective study designed to investigate the antitumor efficacy and tolerability of goserelin with letrozole as first-or second-line hormonal therapy in patients with advanced breast cancer, some of whom had progressed despite multiple prior endocrine and cytotoxic therapies.
Patients and methods

Patients
All premenopausal women who had been treated with goserelin and letrozole for advanced breast cancer in the Cancer Hospital of the Chinese Academy of Medical Sciences were included in the study, having received this regimen as either first-line or secondline endocrine therapy after their metastasis or recurrence. All of them had histologically or cytologically confirmed locally advanced or metastatic breast cancer with progression, as determined by the WHO classification criteria, were on one or more endocrine and cytotoxic treatments, and had positive or unknown estrogen or progesterone receptor status. The patient was considered receptor positive if any assay of primary or secondary tumor tissue was positive. Although both receptors of three patients were unknown, they showed a response to previous tamoxifen treatment. Premenopausal status was defined as the occurrence of menstruation within the last 12 months of study entry, as well as ER, LH and FSH levels within the premenopausal range. All patients had endocrine or systemic cytotoxic or radiation therapy beyond the immediately preceding 4 weeks. All cases had no history of other systemic malignancy, as well as no other serious illnesses that could interfere with compliance. In all patients, ECOG performance status was 0, 1, or 2, and life expectancy was ≥ 3 months. All such as bone lesions, CR was defined as the disappearance of all non-measurable lesions; SD was defined as persistence of one or more non-measurable lesions; and PD referred to unequivocal, overall progression of existing non-measurable lesions.
PFS was defined as the time from the start of goserelin with letrozole therapy until objective disease progression or death from any cause. Overall survival (OS) was calculated as the period from the first dose of goserelin with letrozole to the date of death or the last follow-up. The objective tumor response rate (ORR) was defined as the total proportion of patients with either complete or partial tumor response to goserelin with letrozole therapy. The overall clinical benefit (CB) was taken as the percentage of complete response, partial response, and stable disease ≥ 6 months.
Toxicity evaluation
Adverse events during goserelin plus letrozole treatment were assessed according to the National Cancer Institute Common Toxicity Criteria [11] .
Statistical analysis
Baseline patient characteristics were summarized using descriptive statistics. For the efficacy analysis, the primary efficacy parameters were ORR and CB. For PFS and OS, a Kaplan-Meier curve was generated, and the PFS distributions were compared using the logrank test. Cox-proportional hazard model was used to estimate the hazard ratios and 95% CI for PFS in various factors. A statistically significant difference was defined as p<0.05. The incidence and severity of toxicities were summarized in standard frequency tables. All statistical analyses were performed using SPSS software version 16.0 (SPSS, Chicago, IL).
results
Patient characteristics
A total of 52 patients, with a mean age of 40 (range, 29-49) years were enrolled in the period from May, 2004 to May, 2009. The median duration of goserelin and letrozole treatment was 11 (range, 2-61) months, and the median duration of overall follow-up was 31 (range, 3-66) months. Every patient had achieved amenorrhea since receiving goserelin plus letrozole. Table 1 lists the patients' baseline demographics.
The principal reason for discontinuation was PD in 31 patients (59.6%). Two patients on goserelin and and concomitant medications (within 1 month prior to study entry). While on treatment, tumor assessments were performed every 3 months. The date and cause of death of subjects who received at least one treatment dose of goserelin plus letrozole were collected.
Tumor response was evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) [10] . As this was a single-centre, retrospective trial of goserelin plus letrozole treatment and not a controlled clinical trial, there was no external review of response rates. According to the evaluation of measurable lesions, complete response (CR) was defined as the radiological disappearance of all measurable disease; partial response (PR) was defined as ≥ 30% decrease in tumor size or in the sum of all measurable lesions; and stable disease (SD) was defined as a <30% decrease or a <20% increase in tumor size without the appearance of new lesions. Progressive disease (PD) was defined as a ≥ 20% increase in tumor size or the appearance of new lesions. For the evaluation of non-measurable disease letrozole stopped treatment because they withdrew from the trial. The other 13 patients remained in the study and continued their treatment.
Pretreatment regimens
The previous adjuvant treatment regimens are listed in Table 2 . The numbers and types of previous endocrine and cytotoxic treatment regimens applied in the palliative setting prior to goserelin and letrozole treatment are also given in Table 2 . There were three patients who received no adjuvant treatment because they were stage IV at presentation. Overall, 92.3% of patients had undergone chemotherapy, and 53.8% had also received antihormonal treatment in the adjuvant setting. The mean number of both cytotoxic and endocrine regimens with metastatic disease was 2 (range, 0-4). The distribution of chemotherapy regimens in the palliative setting was as follows: 20 patients had previously received anthracyclines -gemcitabine + epirubicin, three (5.8%), vinorelbine + epirubicin, one (1.9%), epirubicin + taxanes, 16 (30.8%); 19 patients had received capecitabine-based regimens -capecitabine + vinorelbine, eight (15.4%), capecitabine + taxanes, eight (15.4%), gemicitabine + capecitabine, three (5.8%). Twenty-one patients (40.4%) had received taxanes without anthracyclines, and six (11.5%) patients were pretreated with cisplatin + vinorelbine. Trastuzumab was given alone (n=1) or together with taxanes (n=2). Twelve received no cytotoxic therapy.
Sixteen patients received goserelin and letrozole as second-line endocrine treatment. These patients' firstline endocrine regimens included medroxyprogesterone acetate in 2 patients, and tamoxifen or toremifene in the other 14 patients.
Response to treatment
All patients were available for evaluation of response, including 14 patients with non-measurable lesions and 38 with measurable lesions. Two patients stopped after 3 months of treatment; one of them experienced PR when she withdrew from the study. The median duration of response to the treatment was 24 (range, 12-58) months. Two patients reached CR (3.8%), nine patients achieved PR (17.3%), and 29 patients (55.8%) experienced SD, with 26 (50.0%) of them having SD for a period longer than 6 months after goserelin and letrozole therapy. Thus, ORR was 21.1%, and CB was observed in 37 women (71.1%). Primary progressive disease occurred in 31 women (59.6%). At the time of data cut-off, 26 patients (50.0%) had died because of disease progression. The median PFS was 10 (range, 2-61) months, the median OS was 40 (range, 3-66) months.
Independent of the PgR status, CB was achieved in a slightly higher proportion of patients with ER-positive than ER-negative tumor cells. Furthermore, objective (Table 3) . The number of patients with unknown ER and PgR disease was too small to allow any conclusions, but none of them benefited from goserelin and letrozole treatment. The HER2/ neu status was known in 43 women (82.7%, Table 1 ). In our limited data, the CB rate achieved with goserelin and letrozole therapy was comparable between HER2/neupositive and HER2/neu-negative patients (Table 3) .
Nine patients (100%) with only soft tissue metastases derived CB from treatment with goserelin and letrozole, two achieving CR (22.2%), two achieving PR (22.2%), and five (55.6%) achieving SD ≥ 6 months. Overall, ten of 14 women (71.4%) with only bone metastases experienced CB (none of them achieving CR, 0.0%). Patients with bone/soft tissue metastasis had a significantly higher CB ratio (80.8%) than patients with visceral metastasis (53.8%) ( Table 4 ) (p=0.016). Compared with patients with visceral metastases, those without visceral metastases (p=0.034) had significantly favorable prognoses (Fig. 1) .
Two patients with CR received goserelin and letrozole as first-line endocrine treatment, neither of them ever receiving chemotherapy after recurrence. With goserelin and letrozole as second-line, palliative endocrine treatment, two of 16 patients achieved PR, and seven achieved SD ≥ 6 months. It can be seen that goserelin and letrozole conferred CB to more than half of the patients with prior endocrine treatments. There was no significant difference in PFS between using this regimen as first-line and as second-line treatment (p=0.290).
Women with no, one, two, three, and four chemotherapy pretreatments achieved CB in 90.9%, 73.9%, 45.5%, 40.0%, and 0.0% of cases, respectively. No patients in the groups pretreated with two to four lines of chemotherapy reached PR. Ten patients had never received palliative therapy, all of them achieved CB, and two of them achieved CR. Only one of them had visceral metastases. Patients without or with one-line palliative chemotherapy did not show significantly higher CB ratios than patients with more than two lines of chemotherapy (Table 4) . Furthermore, according to PFS, logistic regression analysis showed that no matter how many pretreatments the patients had received, they could still benefit from goserelin and letrozole treatment (p=0.759).
Analyzed by Cox proportional hazards model (Table  5) , those received this regimen with ER positive had significantly longer PFS. However, there was no evidence for differences in other factors such as PgR and HER2 status, DFI, the sites of metastatic diseases, the number of previous endocrine therapies and the number of previous chemotherapies.
Tolerability and safety Table 6 shows the drug-related toxicity in the study. During goserelin and letrozole treatment, adverse effects were reported by 18 patients (34.6%). Overall, treatment was well tolerated, and the most common 
Fig. 1
Progression-free survival of patients with or without visceral metastases patients had received more than second-line chemotherapy for MBC prior to goserelin and letrozole, suggesting that chemotherapy was the preferred choice in Chinese MBC patients for achieving rapid tumor decrease. The present study, which included several subjects with multiple prior endocrine and cytotoxic therapy who achieved CB with goserelin and letrozole treatment, suggests the possibility of maintaining patients on antihormonal treatment who otherwise would have to be changed to cytostatic therapy because of disease progression on endocrine therapy or of changing back to endocrine therapy after previous failed cytotoxic therapy. In addition, our data (unpublished here) indicated that there was no significant difference in their responses to pretreatment. Therefore, the present study confirms that goserelin and letrozole treatment has the potential to halt progression of metastatic, hormone-sensitive, breast cancer and to confer CB on a sizeable proportion of patients progressing on side effects were hot flushes and nausea. All events were grade 1 or 2. Two patients who withdrew from treatment had moderate toxicities, one with grade 2 hot flushes and the other with grade 2 face and foot edema.
Although goserelin and letrozole have not raised safety concerns so far, it should be mentioned that adverse event reporting in the present study was not as rigorous as in a controlled clinical trial setting.
Discussion
The combination of an LH-RH analog and tamoxifen is now accepted as the treatment of choice in premenopausal patients with MBC [12] [13] [14] . Because aromatase inhibitors have proven better than tamoxifen in postmenopausal women with ER-positive breast cancer [15] [16] [17] , the combination of an aromatase inhibitor with ovarian suppression has been studied in clinical trials as an alternative to tamoxifen in premenopausal patients. Combination therapy involving an LH-RH agonist plus anastrozole appeared to be safe and beneficial in premenopausal women with metastatic breast cancer in a study of a relatively small number of patients and short overall follow-up [5] . Though results from direct head-to-head comparisons between letrozole and anastrozole are lacking, some studies confirmed that letrozole is a more potent suppressor than anastrozole of both plasma and tissue estrogen levels in postmenopausal women with breast cancer [18, 19] . Therefore, combined use of goserelin and letrozole might be beneficial in premenopausal patients with advanced breast cancer. In recent phase II study in Korea, premenopausal metastatic breast cancer patients treated with letrozole plus goserelin had the comparable efficacy with postmenopausal patients treated with letrozole alone as first-line hormone therapy [7] .
In our study, 40 (76.9%) patients had received chemotherapy after recurrence or metastasis, and 18 was 3.4 (range, 2.4-4.5) months. Therefore, the drug regimen is not suitable for rapid tumor-mass reduction, particularly in primarily visceral types of metastatic spread. Responses to the drug regimen were different in patients with different metastatic locations, but with the number of women in each group being small, no firm conclusions can be drawn. The best response was observed in patients with only soft-tissue metastases; 100% achieved CB, including the two patients who attained CR. Goserelin and letrozole therapy is a well-tolerated drug regimen, since patients reported only grade 1/2 adverse effects, predominantly hot flushes and nausea. Although two patients discontinued treatment due to adverse events, they experienced only moderate toxicities; one grade 2 hot flushes and the other grade 2 face and foot edema.
Conclusion
In summary, goserelin and letrozole can safely produce complete and partial responses, as well as prolonged disease stabilization, in some previously treated patients with advanced breast cancer. By extending the sequence of palliative therapy, disease progression and the need for chemotherapy may be significantly delayed, potentially extending patient survival rates and improving quality of life. multiple lines of cytotoxic treatments.
Of the 52 women included in our study, two achieved CR (3.8%), and nine developed PR (17.3%). Most patients who achieved CR/PR received goserelin and letrozole as first-line endocrine therapy and had no visceral metastases. Univariate analysis identified several factors related to PFS. Patients without visceral metastases (p=0.034) have significantly favorable prognoses, which was in agreement with the predicted association of visceral metastases with lower response rates to endocrine therapy [20] . Notably, CB was achieved by 71.4% of HER2/neu-positive patients, partially because of the limited number of patients in this group. It is clear that more studies are needed to determine the efficacy of goserelin and letrozole in relation to HER2/ neu status in patients with advanced MBC.
The ORR of 12.5% (2/16) and the CB ratio of 56.3% (9/16) in women treated with goserelin and letrozole as the second-line endocrine treatment is slightly lower than that reported by Forward [5] . The difference may be due to the fact that Forward included only patients who previously responded to goserelin and tamoxifen without palliative chemotherapy. It would appear that the response rate might be higher if only patients who received endocrine therapy as the appropriate treatment option were included. For continuously hormone-sensitive patients, cross-resistance to other drugs often occurred later.
The median time to onset of response in our patients references
